Comparison of Clinical Outcome of 20mg and 40mg Rosuvastatin in patients with ST elevation acute myocardial infarction (STEMI) after Percutaneous Coronary Intervention (PCI) over 2 months
DOI:
https://doi.org/10.55958/jcvd.v19i3.151Keywords:
lipid profile, Percutaneous Coronary Intervention, Rosuvastatin, ST segment elevation myocardial infarction, Myocardial InfarctionAbstract
ABSTRACT:
Background: Diminished or total stoppage of blood circulation to a part of the myocardium leads to myocardial infarction (MI), frequently called "heart attack." MI is by and large associated with coronary artery disease. Atherosclerosis is the predominant cause of CAD. Atherosclerosis is a result of dyslipidemia. Statin is a lipid-lowering medication that also has anti-inflammatory properties, lowers oxidative stress, inhibits thrombogenic responses, stabilizes plaque, and improves endothelial function, resulting in enhanced myocardial perfusion. This research was designed because medical evidence on the advantages of 20mg rosuvastatin versus 40mg rosuvastatin for lowering peri-procedural myocardial injury and post PCI MACE in patients suffering from STEMI is limited in the Pakistani population.
Objective: The goal of this research work was to compare the clinical outcomes of using 20mg and 40mg rosuvastatin following percutaneous coronary intervention (PCI) in individuals suffering from STEMI over 2 months.
Material & Method: For six months, a RCT was conducted in the Cardiology department of Mayo Hospital, Lahore. Sixty-six patients were included after fulfilling the inclusion and exclusion criteria. Individuals enrolled in this trial were randomized to 2 groups: group A, in which patients were given 20 mg Rosuvastatin and group B, in which patients were given 40mg Rosuvastatin. All patients received PCI by experienced interventional cardiologists. Clopidogrel was prescribed for a year after the intervention, and aspirin was prescribed for lifelong. After 24 hours, 1 week, 6 weeks, and 2 months, patients in both groups were re-evaluated clinically.
Results: The patient’s mean age was 48.42±9.127 years, with 51 (77.27%) of them being male and 25 (37.86%) of them being diabetic. In terms of quantitative TnI, CKMB, ALT, HDL, LDL, TG, TC, and HbA1c, there was no significant difference among the two groups. Tolerability for both 20mg and 40 mg rosuvastatin was 100 percent at the end of the second month. In both groups, no MACE was found.
Conclusion: This research concluded that 40 mg rosuvastatin is just as safe and well tolerated as 20 mg rosuvastatin. After two months of PCI in individuals suffering from STEMI, both intensities are equally effective in terms of clinical outcome.
References
References
Nowbar AN, Gitto M, Howard JP, Francis DP, Al-Lamee R. Mortality from ischemic heart disease: Analysis of data from the World Health Organization and coronary artery disease risk factors From NCD Risk Factor Collaboration. Circulation: cardiovascular quality and outcomes. 2019;12(6):e005375.
Ioacara S, Popescu AC, Tenenbaum J, Dimulescu DR, Popescu MR, Sirbu A, et al. Acute myocardial infarction mortality rates and trends in Romania between 1994 and 2017. International Journal of Environmental Research and Public Health. 2020;17(1):285.
Khan MA, Hashim MJ, Mustafa H, Baniyas MY, Al Suwaidi SKBM, AlKatheeri R, et al. Global epidemiology of ischemic heart disease: results from the global burden of disease study. Cureus. 2020;12(7).
Diabetesatlas.org. [cited 2022 Feb 22]. Available from: https://diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_Edition_ 2021.pdf
Ramana RK, Lewis BE. Percutaneous Coronary Intervention in patients with acute coronary syndrome: focus on bivalirudin. Vascular health and risk management. 2008;4(3):493.
Godino C, Colombo A. Complications of Percutaneous Coronary Intervention. In: PanVascular Medicine. Berlin, Heidelberg: Springer Berlin Heidelberg; 2014. p. 1–30.
Sun Y, Qi G, Gao Y, Zhang H, Pang X, Zhao W, et al. Effect of different
loading doses of atorvastatin on percutaneous coronary intervention for acute coronary syndromes. Canadian Journal of Cardiology. 2010;26(9):481-5.
Fourth universal definition of myocardial infarction: What’s new? [Internet]. American College of Cardiology. [cited 2022 Feb 27]. Available from: https://www.acc.org/latest-in-cardiology/articles/2018/11/16/09/06/fourth-universal-definition-of-mi
Members* WC, Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124(23):2574-609.
Gencer B, Giugliano RP. Management of LDL?cholesterol after an acute coronary syndrome: Key comparisons of the American and European clinical guidelines to the attention of the healthcare providers. Clinical Cardiology. 2020;43(7):684-90.
Rusnak J, Behnes M, Schupp T, Lang S, Reiser L, Taton G, et al. Statin therapy is associated with improved survival in patients with ventricular tachyarrhythmias. Lipids in health and disease. 2019;18(1):1-11.
Kim JW, Yun KH, Kim EK, Kim YC, Joe D-Y, Ko JS, et al. Effect of high dose rosuvastatin loading before primary percutaneous coronary intervention on infarct size in patients with ST-segment elevation myocardial infarction. Korean Circulation Journal. 2014;44(2):76-81.
Jiang F, Yang J, Zhang L, Li R, Zhuo L, Sun L, et al. Rosuvastatin reduces ischemia?reperfusion injury in patients with acute coronary syndrome treated with percutaneous coronary intervention. Clinical Cardiology. 2014;37(9):530-5.
Pan Y, Tan Y, Li B, Li X. Efficacy of high-dose rosuvastatin preloading in patients undergoing percutaneous coronary intervention: a meta-analysis of fourteen randomized controlled trials. Lipids in health and disease. 2015;14(1):1-12.
Yun KH, Oh SK, Rhee SJ, Yoo NJ, Kim N-H, Jeong J-W. 12-month follow-up results of high dose rosuvastatin loading before percutaneous coronary intervention in patients with acute coronary syndrome. International journal of cardiology. 2011;146(1):68-72.
Shah CP, Shah BP, Dani SI, Channa B, Lakshmanan S, Krishnamani N, et al. Efficacy and safety of the intensive dose of rosuvastatin 40 mg/day in patients with acute coronary syndrome and at high risk of cardiovascular disease-ROSUVEES-2. Indian heart journal. 2016;68(6):766-71.
Brener S, Ellis S, Schneider J, Topol E. Frequency and long-term impact of
myonecrosis after coronary stenting. European heart journal. 2002;23(11):869-76.
Ioannidis JP, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. Journal of the American College of Cardiology. 2003;42(8):1406-11.
Veselka J, Zemánek D, Hájek P, Malý M, Adlová R, Martinkovi?ová L, et al. Effect of two-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study. The American journal of cardiology. 2009;104(5):630-3.
Veselka J, Hájek P, Tomašov P, Tesa? D, Br?hová H, Mat?jovi? M, et al. Effect of rosuvastatin therapy on troponin I release following percutaneous coronary intervention in nonemergency patients (from the TIP 3 study). The American journal of cardiology. 2014;113(3):446-51.
Godino C, Pavon AG, Mangieri A, Salerno A, Cera M, Monello A, et al. Platelet reactivity in response to loading dose of atorvastatin or rosuvastatin in patients with stable coronary disease before percutaneous coronary intervention: The STATIPLAT randomized study. Clin Cardiol. 2017;40(8):605–11.
Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. Journal of the American College of Cardiology. 2009;54(6):558-65.
Ye Z, Lu H, Su Q, Guo W, Dai W, Li H, et al. Effect of high-dose rosuvastatin loading before percutaneous coronary intervention in Chinese patients with acute coronary syndrome: A systematic review and meta-analysis. PLoS One. 2017;12(2):e0171682.
Benjo AM, El?Hayek GE, Messerli F, DiNicolantonio JJ, Hong MK, Aziz EF, et al. High dose statin loading prior to percutaneous coronary intervention decreases cardiovascular events: a meta?analysis of randomized controlled trials. Catheterization and Cardiovascular Interventions. 2015;85(1):53-60.
Tsimikas S. High-dose statins prior to percutaneous coronary intervention: a paradigm shift to influence clinical outcomes in the cardiac catheterization laboratory. American College of Cardiology Foundation Washington, DC; 2009. p. 2164-6.
Cay S, Cagirci G, Sen N, Balbay Y, Durmaz T, Aydogdu S. Prevention of peri-procedural myocardial injury using a single high loading dose of rosuvastatin. Cardiovascular drugs and therapy. 2010;24(1):41-7.
Shah CP, Shah BP, Dani SI, Channa BB, Lakshmanan SS, Krishnamani NC, et al. Efficacy and safety of the intensive dose of rosuvastatin 40mg/day in patients with
acute coronary syndrome and at high risk of cardiovascular disease-ROSUVEES-2. Indian Heart J. 2016 Nov-Dec;68(6):766-71.
Walker G, The NNT Group. Statins for heart disease prevention (with known heart disease) – [Internet]. TheNNT. [cited 2022 Apr 1]. Available from: https://www.thennt.com/nnt/statins-for-heart-disease-prevention-with-known-heart-disease/
Ridker PM. The JUPITER trial: results, controversies, and implications for prevention: Results, controversies, and implications for prevention. Circ Cardiovasc Qual Outcomes [Internet]. 2009;2(3):279–85. Available from: http://dx.doi.org/10.1161/CIRCOUTCOMES.109.868299
